2/3
08:00 am
abus
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts [Seeking Alpha]
Medium
Report
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts [Seeking Alpha]
1/23
05:06 am
abus
Arbutus Biopharma (NASDAQ:ABUS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Arbutus Biopharma (NASDAQ:ABUS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.